Skip to content

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170929003
Enrollment
650
Registered
2017-09-29
Start date
2017-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non&#45

Interventions

Study Drugs/EU&#45
Approved Avastin/Carboplatin/Paclitaxel
Active Comparator Drug

Sponsors

mAbxience S.A
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - Males and female subjects aged 18 years or above to less than or equal to 80 years - Signed informed consent must be obtained before initiation of any study-specific procedures or treatment as confirmation of the subject’s awareness and willingness to comply with the study requirements. - Subjects should have newly diagnosed or recurrent Stage IIIB/IV nonsquamous NSCLC (defined by seventh edition of the TNM classification for Lung Cancer, 2010) not amenable to curative intent surgery, and not have received any systemic therapy for advanced disease. For subjects with recurrent disease, at least 6 months must have elapsed from previous adjuvant treatment.

Exclusion criteria

Exclusion criteria: Inability to comply with protocol procedures

Design outcomes

Primary

MeasureTime frame
Objective Response Rate measurment at week 18 18 months By RECIST Criteria

Secondary

MeasureTime frame
Progress-free survial measurment at week 18 and week 52 18 and 52 weeks By RECIST Criteria

Countries

Thailand

Contacts

Public ContactDr. Manoch Buranachokphaisan

Buddhachinnaraj Phitsanulok Hospital

nawath.yapuang@incresearch.com055270300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026